| Cascade Family Medicine, P.s. | |
|
406 Se 131st Ave Suite 203 B Vancouver WA 98683-4004 | |
| (360) 254-4402 | |
| (360) 892-9241 |
| Full Name | Cascade Family Medicine, P.s. |
|---|---|
| Speciality | Family Medicine |
| Location | 406 Se 131st Ave, Vancouver, Washington |
| Authorized Official Name and Position | Lawrence Edward Foltz (PRESIDENT) |
| Authorized Official Contact | 3602544402 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Cascade Family Medicine, P.s. 406 Se 131st Ave Suite 203 Vancouver WA 98683-4004 Ph: (360) 254-4402 | Cascade Family Medicine, P.s. 406 Se 131st Ave Suite 203 B Vancouver WA 98683-4004 Ph: (360) 254-4402 |
| NPI Number | 1063622355 |
|---|---|
| Provider Enumeration Date | 05/23/2007 |
| Last Update Date | 08/22/2020 |
| Medicare PECOS PAC ID | 5890851943 |
|---|---|
| Medicare Enrollment ID | O20090225000717 |
News Archive
Chemists at the University at Buffalo have used rational drug design to synthesize small, cell-permeable molecules that are effective in vitro against two common types of myotonic muscular dystrophy, a result that has implications for potentially curing muscular dystrophy, as well as other diseases.
"Taking out the trash" takes on a whole new meaning, as investigators at The Cancer Institute of New Jersey (CINJ) and Rutgers, The State University of New Jersey, have discovered that a waste disposal protein is the key to cancer tumor suppression in a process known as autophagy. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.
A large study has shown that children of mothers who are anxious during pregnancy and in the first few years of the child's life have twice the risk of having hyperactivity symptoms at age 16.
MicroBiome Therapeutics LLC, today announced that data from the company's clinical trial of microbiome modulator NM504 in development for type 2 diabetes and prediabetes has been accepted for a Poster Preview Presentation at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and The Endocrine Society.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063622355 | NPI | - | NPPES |
| 7051428 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (Washington) | Primary |
| Provider Name | Lawrence E Foltz |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1952376196 PECOS PAC ID: 1951202225 Enrollment ID: I20040119000735 |
News Archive
Chemists at the University at Buffalo have used rational drug design to synthesize small, cell-permeable molecules that are effective in vitro against two common types of myotonic muscular dystrophy, a result that has implications for potentially curing muscular dystrophy, as well as other diseases.
"Taking out the trash" takes on a whole new meaning, as investigators at The Cancer Institute of New Jersey (CINJ) and Rutgers, The State University of New Jersey, have discovered that a waste disposal protein is the key to cancer tumor suppression in a process known as autophagy. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.
A large study has shown that children of mothers who are anxious during pregnancy and in the first few years of the child's life have twice the risk of having hyperactivity symptoms at age 16.
MicroBiome Therapeutics LLC, today announced that data from the company's clinical trial of microbiome modulator NM504 in development for type 2 diabetes and prediabetes has been accepted for a Poster Preview Presentation at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and The Endocrine Society.
› Verified 7 days ago
| Provider Name | Sherilyn Marie Foltz Cook |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1013114586 PECOS PAC ID: 7416013198 Enrollment ID: I20090304000537 |
News Archive
Chemists at the University at Buffalo have used rational drug design to synthesize small, cell-permeable molecules that are effective in vitro against two common types of myotonic muscular dystrophy, a result that has implications for potentially curing muscular dystrophy, as well as other diseases.
"Taking out the trash" takes on a whole new meaning, as investigators at The Cancer Institute of New Jersey (CINJ) and Rutgers, The State University of New Jersey, have discovered that a waste disposal protein is the key to cancer tumor suppression in a process known as autophagy. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.
A large study has shown that children of mothers who are anxious during pregnancy and in the first few years of the child's life have twice the risk of having hyperactivity symptoms at age 16.
MicroBiome Therapeutics LLC, today announced that data from the company's clinical trial of microbiome modulator NM504 in development for type 2 diabetes and prediabetes has been accepted for a Poster Preview Presentation at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and The Endocrine Society.
› Verified 7 days ago
News Archive
Chemists at the University at Buffalo have used rational drug design to synthesize small, cell-permeable molecules that are effective in vitro against two common types of myotonic muscular dystrophy, a result that has implications for potentially curing muscular dystrophy, as well as other diseases.
"Taking out the trash" takes on a whole new meaning, as investigators at The Cancer Institute of New Jersey (CINJ) and Rutgers, The State University of New Jersey, have discovered that a waste disposal protein is the key to cancer tumor suppression in a process known as autophagy. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.
A large study has shown that children of mothers who are anxious during pregnancy and in the first few years of the child's life have twice the risk of having hyperactivity symptoms at age 16.
MicroBiome Therapeutics LLC, today announced that data from the company's clinical trial of microbiome modulator NM504 in development for type 2 diabetes and prediabetes has been accepted for a Poster Preview Presentation at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and The Endocrine Society.
› Verified 7 days ago
Oregon Health & Science University - Vancouver Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 700 Ne 87th Ave, Suite 110, Vancouver, WA 98664 Phone: 360-882-2778 Fax: 360-604-1720 | |
Advanced Gastroenterology, Pllc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2415 Ne 134th St, Suite 205, Vancouver, WA 98686 Phone: 360-576-5060 Fax: 360-576-1133 | |
Amg Of Washington, Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 302 E 37th St, Vancouver, WA 98663 Phone: 888-506-1858 | |
Cascade Park Medical Office Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 12607 Se Mill Plain Blvd, Cascade Park Medical Office, Vancouver, WA 98684 Phone: 800-813-2000 | |
Orchards Medical Office Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 7101 Ne 137th Ave, Vancouver, WA 98682 Phone: 800-813-2000 Fax: 503-286-6879 | |
Sea-mar Community Health Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 7410 Delaware Ln, Vancouver, WA 98664 Phone: 360-896-5128 Fax: 360-896-5179 |